-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E/Sl8T855iURC9diKrNOPHDnqH3RtgE80b+gnPUKtoArFzwBHgMfk9NuSX8VF5Kd g/M3EkHfEzVSAG7qf5gbDg== 0000946486-06-000012.txt : 20060105 0000946486-06-000012.hdr.sgml : 20060105 20060105170346 ACCESSION NUMBER: 0000946486-06-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060103 FILED AS OF DATE: 20060105 DATE AS OF CHANGE: 20060105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZODDA DENI M PHD CENTRAL INDEX KEY: 0001139219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26422 FILM NUMBER: 06513624 BUSINESS ADDRESS: STREET 1: 350 SOUTH MAIN STREET STREET 2: SUITE 307 CITY: DOYELSTOWN STATE: PA ZIP: 18901 MAIL ADDRESS: STREET 1: 350 SOUTH MAIN STREET STREET 2: SUITE 307 CITY: DOYELSTOWN STATE: PA ZIP: 18901-4874 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DISCOVERY LABORATORIES INC /DE/ CENTRAL INDEX KEY: 0000946486 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171943 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2600 KELLY ROAD STREET 2: SUITE 100 CITY: WARRINGTON STATE: PA ZIP: 18976 BUSINESS PHONE: 2154889300 MAIL ADDRESS: STREET 1: 2600 KELLY ROAD STREET 2: SUITE 100 CITY: WARRINGTON STATE: PA ZIP: 18976 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19961121 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN INC DATE OF NAME CHANGE: 19950609 4 1 primary_doc.xml PRIMARY DOCUMENT X0202 4 2006-01-03 0 0000946486 DISCOVERY LABORATORIES INC /DE/ DSCO 0001139219 ZODDA DENI M PHD DISCOVERY LABORATORIES, INC. 2600 KELLY ROAD, SUITE 100 WARRINGTON PA 18976-3646 0 1 0 0 Sr VP, Business Development Common Stock 2005-07-21 5 A 0 E 271 6.461 A 7677 D Common Stock 2005-10-21 5 A 0 E 272 6.45 A 7949 D Common Stock 2006-01-03 4 A 0 4000 0 A 11949 D Incentive Stock Option (right to buy) 7.01 2006-01-03 4 A 0 25000 0 A 2006-01-03 2016-01-03 Common Stock 25000 25000 D Transaction reported on Table I represents Issuer's matching stock contribution pursuant to 401(k) plan. New restricted stock award shall fully vest on the date that Surfaxin for RDS first becomes widely commercially available, as such date is determined by the Company. This employee stock option shall vest 25% on the date of the grant, and the balance shall vest in a series of three successive equal annual installments beginning with the first year anniversary of the grant. Deni M. Zodda 2006-01-05 -----END PRIVACY-ENHANCED MESSAGE-----